search
Back to results

Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

Primary Purpose

Cocaine-Related Disorders, Opioid-Related Disorders

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Disulfiram
Sponsored by
University of Arkansas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring Cocaine Abuse

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: History of cocaine use at least once a week during the month prior to study entry Urine screen tests positive for cocaine Meets DSM-IV criteria for opioid- and cocaine-dependence Urine toxicology screen tests negative for benzodiazepines prior to beginning methadone treatment Exclusion Criteria: Current drug or alcohol dependence other than opiates, cocaine, or tobacco Significant medical condition, such as abnormal liver function (with laboratory findings greater than three times normal), active hepatitis, or high blood pressure Current cardiac condition Occult coronary artery disease At high risk for cardiovascular disease, seizure disorders, or any other significant underlying medical condition that may make treatment with disulfiram or methadone unsafe Meets DSM-IV psychiatric diagnostic criteria for lifetime schizophrenia, bipolar disorder, or other psychotic disorders Currently suicidal or homicidal Currently taking a prescribed psychotropic medication that cannot be discontinued Pregnant Currently taking metronidazole or clotrimazole

Sites / Locations

  • University of Arkansas for Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Placebo

Disulfiram at 62.5 mg

Disulfiram at 125 mg

Disulfiram at 250 mg

Arm Description

Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.

Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.

Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.

Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.

Outcomes

Primary Outcome Measures

Cocaine use
Urine toxicology screens were conducted thrice-weekly for 14 weeks.

Secondary Outcome Measures

Full Information

First Posted
September 20, 2005
Last Updated
January 26, 2012
Sponsor
University of Arkansas
Collaborators
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT00218608
Brief Title
Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone
Official Title
Disulfiram for Cocaine Abuse in Methadone- Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
April 2001 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
January 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Arkansas
Collaborators
Yale University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cocaine is an extremely addictive stimulant drug that directly affects the brain. It is used in several different forms and can be snorted, smoked, or injected to achieve the desired effect. Cocaine users are at risk for many health problems, both directly and indirectly related to the effects of cocaine. Disulfiram, a drug used to treat chronic alcoholism, may be effective in reducing cocaine use. This study will evaluate the effectiveness of three different doses of disulfiram in treating cocaine dependence in opioid- and cocaine-dependent individuals maintained on methadone.
Detailed Description
Despite the harm that cocaine can cause to the body, its abuse is widespread. It is the cause of more visits to hospital emergency rooms nationwide than any other illegal drug. Effective treatments for cocaine and opiate addictions are essential to the decline of cocaine- and opiate-related disorders. Unfortunately, cocaine use remains prevalent among participants in many opioid maintenance programs. The addition of other medications to methadone maintenance may prove helpful in reducing cocaine use. Disulfiram, a drug used to treat chronic alcoholism, causes unpleasant effects when even small amounts of alcohol are consumed. This study will evaluate the effectiveness of three different doses of disulfiram in treating cocaine dependence in opioid- and cocaine-dependent individuals maintained on methadone. Participants in this double blind study will be randomly assigned to receive either disulfiram at one of three dosage levels (62.5, 125, 250 mg/day) or placebo for 14 weeks. During the first 2 weeks, doses of methadone plus either disulfiram or placebo will be administered until the assigned maintenance dose is achieved. This dosage level will be maintained for the duration of the study. Participants will be required to report to the study site Monday through Saturday of each week for assessments and to receive medication. They will receive a take-home dose of medication for Sunday. In addition, participants will receive a weekly session of cognitive-behavioral therapy. Urine samples will be collected three times a week to assess drug use. At the end of the study, participants will undergo a 4- to 6-week detoxification period in which they will gradually discontinue the use of methadone and disulfiram. All participants have the option to request transfer to a local methadone maintenance program instead of undergoing detoxification. Enrollment has been completed and no subjects are active. Data analyses are being conducted at this time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders, Opioid-Related Disorders
Keywords
Cocaine Abuse

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
158 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
Arm Title
Disulfiram at 62.5 mg
Arm Type
Active Comparator
Arm Description
Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
Arm Title
Disulfiram at 125 mg
Arm Type
Active Comparator
Arm Description
Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
Arm Title
Disulfiram at 250 mg
Arm Type
Active Comparator
Arm Description
Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
Intervention Type
Drug
Intervention Name(s)
Disulfiram
Other Intervention Name(s)
Antabuse
Intervention Description
Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
Primary Outcome Measure Information:
Title
Cocaine use
Description
Urine toxicology screens were conducted thrice-weekly for 14 weeks.
Time Frame
14 wks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: History of cocaine use at least once a week during the month prior to study entry Urine screen tests positive for cocaine Meets DSM-IV criteria for opioid- and cocaine-dependence Urine toxicology screen tests negative for benzodiazepines prior to beginning methadone treatment Exclusion Criteria: Current drug or alcohol dependence other than opiates, cocaine, or tobacco Significant medical condition, such as abnormal liver function (with laboratory findings greater than three times normal), active hepatitis, or high blood pressure Current cardiac condition Occult coronary artery disease At high risk for cardiovascular disease, seizure disorders, or any other significant underlying medical condition that may make treatment with disulfiram or methadone unsafe Meets DSM-IV psychiatric diagnostic criteria for lifetime schizophrenia, bipolar disorder, or other psychotic disorders Currently suicidal or homicidal Currently taking a prescribed psychotropic medication that cannot be discontinued Pregnant Currently taking metronidazole or clotrimazole
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alison Oliveto, PhD
Organizational Affiliation
UAMS
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Arkansas for Medical Sciences
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205 7911
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

We'll reach out to this number within 24 hrs